Journal of Innate Immunity, Journal Year: 2024, Volume and Issue: unknown
Published: May 20, 2024
We aimed to elucidate the inflammatory response of Aspergillus fumigatus conidia in a whole-blood model innate immune activation and compare it with well-characterized reaction Escherichia coli.
Language: Английский
Nature Reviews Microbiology, Journal Year: 2023, Volume and Issue: 21(12), P. 818 - 832
Published: Aug. 30, 2023
Language: Английский
Citations
137
Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)
Published: Sept. 20, 2024
Language: Английский
Citations
43
Journal of Fungi, Journal Year: 2024, Volume and Issue: 10(4), P. 251 - 251
Published: March 27, 2024
Aspergillosis is a fungal infection caused by various species of Aspergillus, most notably A. fumigatus. This fungus causes spectrum diseases, including allergic bronchopulmonary aspergillosis, aspergilloma, chronic pulmonary and invasive aspergillosis. The clinical manifestations severity aspergillosis can vary depending on individual immune status the specific Aspergillus involved. recognition involves pathogen-associated molecular patterns (PAMPs) such as glucan, galactomannan, mannose, conidial surface proteins. These are recognized pathogen receptors present cells Toll-like (TLR-1,2,3,4, etc.) C-type lectins (Dectin-1 Dectin-2). We discuss roles cytokines in from both perspective human experimental infection. Several chemokines have been implicated response to infection, interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), CCR4, CCR17, other interleukins. For example, (ABPA) characterized Th2 Th9 cell-type immunity interleukin (IL)-4, IL-5, IL-13, IL-10. In contrast, it has observed that Th1 Th17 via IFN-γ, IL-1, IL-6, IL-17. activate stimulate production molecules, antimicrobial peptides reactive oxygen species, which aid clearance pathogen. Moreover, they help initiate coordinate response, recruit site promote fungus. Insight into host animal studies may understanding possibly leading harnessing power or cytokine (receptor) antagonists transforming them precise immunotherapeutic strategies. could advance personalized medicine.
Language: Английский
Citations
17
Mycology: An International Journal on Fungal Biology, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 14
Published: March 10, 2025
Language: Английский
Citations
1
Pharmaceutics, Journal Year: 2023, Volume and Issue: 15(11), P. 2582 - 2582
Published: Nov. 3, 2023
Airway mucus dysfunction and impaired immunological defenses are hallmarks of several lung diseases, including asthma, cystic fibrosis, chronic obstructive pulmonary mostly causative factors in bacterial-biofilm-associated respiratory tract infections. Bacteria residing within the biofilm architecture pose a complex challenge clinical settings due to their increased tolerance currently available antibiotics host immune responses, resulting infections with high recalcitrance rates morbidity mortality. To address these unmet needs, potential anti-biofilm therapeutic strategies being developed effectively control bacterial biofilm. This review focuses on recent advances development application nanoparticulate drug delivery systems for treatment biofilm-associated infections, especially addressing barriers concern accessibility various types nanoparticles used combat biofilms. Understanding obstacles facing biofilms nanoparticle-based approaches combatting may encourage researchers explore promising modalities
Language: Английский
Citations
18
Microbiology and Molecular Biology Reviews, Journal Year: 2025, Volume and Issue: unknown
Published: Feb. 10, 2025
SUMMARY Advances in modern medical therapies for many previously intractable human diseases have improved patient outcomes. However, successful disease treatment outcomes are often prevented due to invasive fungal infections caused by the environmental mold Aspergillus fumigatus . As contemporary antifungal not experienced same robust advances as other therapies, defining mechanisms of A. initiation and progression remains a critical research priority. To this end, World Health Organization recently identified priority pathogen Centers Disease Control has highlighted emergence triazole-resistant isolates. The expansion diversity host populations susceptible aspergillosis complex dynamic genotypic phenotypic call reinvigorated assessment pathobiological drug-susceptibility mechanisms. Here, we summarize recent advancements field discuss challenges our understanding heterogeneity its pathogenesis diverse populations.
Language: Английский
Citations
1
Infection and Drug Resistance, Journal Year: 2024, Volume and Issue: Volume 17, P. 427 - 439
Published: Feb. 1, 2024
Purpose: The objective of this study was to determine the clinical distribution, in vitro antifungal susceptibility and underlying resistance mechanisms Aspergillus fumigatus ( A. ) isolates from General Hospital Ningxia Medical University between November 2021 May 2023. Methods: Antifungal testing performed using Sensititre YeastOne YO10, with high minimal inhibitory concentrations (MICs) were further confirmed standard broth microdilution assays established by Clinical Laboratory Standards Institute (CLSI) M38-third edition. Whole-Genome Resequencing RT-qPCR azole-resistant strains investigate mechanisms. Results: Overall, a total 276 identified various departments, showing an increasing trend number over past 3 years. Two (0.72%) observed, one which showed overexpression cyp51A, cyp51B, cdr1B, MDR1/2, artR, srbA, erg24A , erg4B but no cyp51A mutation. However, other strain harbored two alterations sequences (L98H/S297T). Therefore, we first described Ningxia, China, reported that has L98H/S297T mutations gene without any tandem repeat (TR) promoter region. Conclusions: This emphasizes importance enhancing attention surveillance particularly those non-TR point or non- mutations, order gain better understanding their prevalence spread Keywords: azole resistance, mutation,
Language: Английский
Citations
6
Nature Microbiology, Journal Year: 2024, Volume and Issue: 9(10), P. 2710 - 2726
Published: Aug. 27, 2024
Language: Английский
Citations
6
Journal of Fungi, Journal Year: 2023, Volume and Issue: 9(11), P. 1084 - 1084
Published: Nov. 6, 2023
Chronic pulmonary aspergillosis (CPA) is a chronic progressive lung disease associated with poor prognosis and 5-year mortality rate of approximately 40-50%. The characterized by slowly destruction the parenchyma, in form multiple cavities, nodules, infiltrates or fibrosis. CPA can be challenging to diagnose due its non-specific symptoms similarities other respiratory conditions combined awareness medical community about disease. This result delayed treatment even for years worsening patient's condition. Serological tests certainly play significant role diagnosing but cannot interpreted without radiological confirmation CPA. Although many data are published on this hot topic, there yet no single definitive test CPA, multidisciplinary approach which involves combination clinical picture, findings, microbiological results exclusion mimicking diseases, essential accurate diagnosis
Language: Английский
Citations
10
Seminars in Respiratory and Critical Care Medicine, Journal Year: 2024, Volume and Issue: 45(01), P. 128 - 140
Published: Jan. 29, 2024
Abstract In the last decade, fungal respiratory diseases have been increasingly investigated for their impact on clinical course of people with cystic fibrosis (CF), a particular focus infections caused by Aspergillus spp. The most common organisms from this genus detected cultures are fumigatus and terreus, followed flavus, niger, nidulans. These species identified to be both chronic colonizers sources active infection may negatively lung function in CF. This review article discusses definitions aspergillosis, challenges practice, current literature available laboratory findings, diagnosis, treatment options pulmonary
Language: Английский
Citations
3